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ABSTRACT
Following administration at subanesthetic doses, (R,S)-ketamine
(ketamine) induces rapid and robust relief from symptoms of
depression in treatment-refractory depressed patients. Previous
studies suggest that ketamine’s antidepressant properties involve
enhancement of dopamine (DA) neurotransmission. Ketamine is
rapidly metabolized to (2S,6S)- and (2R,6R)-hydroxynorketamine
(HNK), which have antidepressant actions independent of N-
methyl-D-aspartate glutamate receptor inhibition. These antide-
pressant actions of (2S,6S;2R,6R)-HNK, or other metabolites, as
well as ketamine’s side effects, including abuse potential, may be
related to direct effects on components of the dopaminergic
(DAergic) system. Here, brain and blood distribution/clearance
and pharmacodynamic analyses at DA receptors (D1–D5) and the
DA, norepinephrine, and serotonin transporters were assessed for
ketamine and its major metabolites (norketamine, dehydronorketa-
mine, and HNKs). Additionally, we measured electrically evoked
mesolimbic DA release and decay using fast-scan cyclic
voltammetry following acute administration of subanesthetic
doses of ketamine (2, 10, and 50mg/kg, i.p.). Following ketamine
injection, ketamine, norketamine, and multiple hydroxynorke-
tamines were detected in the plasma and brain of mice.
Dehydronorketamine was detectable in plasma, but concentra-
tions were below detectable limits in the brain. Ketamine did not
alter the magnitude or kinetics of evoked DA release in the
nucleus accumbens in anesthetized mice. Neither ketamine’s
enantiomers nor its metabolites had affinity for DA receptors or
the DA, noradrenaline, and serotonin transporters (up to 10 mM).
These results suggest that neither the side effects nor antide-
pressant actions of ketamine or ketamine metabolites are associ-
ated with direct effects onmesolimbic DAergic neurotransmission.
Previously observed in vivo changes in DAergic neurotransmission
following ketamine administration are likely indirect.
Introduction
A single subanesthetic dose of (R,S)-ketamine (ketamine)
produces rapid and sustained antidepressant effects in hu-
mans (Berman et al., 2000; Zarate et al., 2006; 2012; aan het
Rot et al., 2010; Diazgranados et al., 2010; Murrough et al.,
2013). Although the discovery of ketamine’s antidepressant
efficacy was a major breakthrough, ketamine’s clinical use is
limited due to its serious side effects, which include dissoci-
ation and abuse potential (Krystal et al., 1994; Morgan and
Curran, 2012).
Evidence suggests that ketamine’s antidepressant actions
might involve its actions on the dopaminergic (DAergic)
system. Administration of ketamine reversed depression-
related deficits in dopamine (DA)-dependent synaptic plastic-
ity, which was associated with its ability to reverse helpless
behavior in rats (Belujon and Grace, 2014). In addition,
haloperidol, presumably acting as a D2 receptor antagonist,
blocked the antidepressant effects of ketamine in the mouse
forced-swim test, whereas activation of D2/D3 receptors en-
hanced its antidepressant effects (Li et al., 2015). These
findings, along with the well established role of the DAergic
system in the pathophysiology and treatment of depression
(Willner et al., 2005; Papakostas, 2006; Dunlop and Nemeroff,
2007; Grace, 2016), suggest that ketamine might act via the
regulation of the DAergic neurotransmission to exert its
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antidepressant effects. In fact, several agents that directly act
on the DAergic system, including pramipexole (a D2/D3 re-
ceptor agonist), bupropion (DA reuptake inhibitor), and mono-
amine oxidase inhibitors, have shown efficacy in the treatment
of depression (Nieuwstraten and Dolovich, 2001; Zarate et al.,
2004; Shulman et al., 2013). Since we have recently demon-
strated that ketamine’s antidepressant effects in mice are the
result of the metabolite (2S,6S;2R,6R)-hydroxynorketamine
(HNK) (Zanos et al., 2016), we hypothesize that direct effects of
ketamine and/or its metabolites at DA receptors and mono-
amine transporters might exist and contribute to these anti-
depressant properties or side effects.
The possible mechanistic link between ketamine, the DA
system, and behavioral changes is further supported by
previous studies in rodents. Both haloperidol and destruction
of catecholaminergic terminals with 6-hydroxydopamine at-
tenuated ketamine-induced hyperlocomotion in mice (Irifune
et al., 1991). Additionally, ketamine reversed haloperidol-
induced catalepsy in rats (Lannes et al., 1991) and enhanced
D2 agonist quinpirole-induced hyperlocomotion (Witkin et al.,
2016). Haloperidol and the D2 antagonist raclopride reversed
the disruptive effect of ketamine on spatial delayed alterna-
tion performance (Verma and Moghaddam, 1996). Further-
more, pretreatment with a D1/D5 receptor antagonist
prevented ketamine-induced hippocampal synaptic depres-
sion and its associated spatial memory deficits in freely
moving rats (Duan et al., 2013). Administration of ketamine
also enhanced the interoceptive stimulus properties of meth-
amphetamine in a rat drug discrimination paradigm (Wooters
et al., 2011). In situ receptor binding studies indicated that
ketamine has a strong affinity for the rat D2 receptor (Kapur
and Seeman, 2002). However, positron emission tomography
has not shown any effects of ketamine administration on these
receptors in humans (Aalto et al., 2002).
Ketamine administration was recently shown to increase
the number of spontaneously active DA neurons in the ventral
tegmental area (VTA) (Belujon and Grace, 2014; Witkin et al.,
2016), and to increase the firing rate and burst firing of these
cells (Belujon and Grace, 2014). Similarly, in humans, keta-
mine enhances amphetamine-induced augmentation of striatal
DA release (Kegeles et al., 2000). However, conflicting data
exist as well. Ketamine has been reported to increase (Irifune
et al., 1991; Verma and Moghaddam, 1996; Witkin et al.,
2016), to have no effect (Lannes et al., 1991; Micheletti et al.,
1992), or to decrease (Rao et al., 1989) striatal DA turnover, or
extracellular DA dialysate levels. Stereoselective effects of
ketamine on DA release in rat striatal slices have been
reported (Hancock and Stamford, 1999; Tso et al., 2004).
Thus, although overall changes in extracellular DA concen-
trations have been assessed previously, there is no consensus
effect, and the low temporal resolution of microdialysis does
not permit a determination of the relative contributions of DA
release by axon terminals or the dynamics of DA reuptake.
Here, we used fast-scan cyclic voltammetry (FSCV) to assess
the effects of ketamine treatment on the magnitude and
temporal dynamics of DA release, and the reuptake of
extracellular DA, in the nucleus accumbens (NAc) core
in vivo. We also performed an in vitro pharmacological affinity
screening of (S)- and (R)-enantiomers of ketamine and its
principal metabolites, (R)- and (S)-norketamine, (2S,6S)-HNK,
(2R,6R)-HNK, (2S,6R)-HNK, (2R,6S)-HNK, and (R)- and
(S)-dehydronorketamines (DHNKs) on DA D1–D5 receptors
and monoamine transporters. Finally, we functionally exam-
ined possible agonist and antagonist actions of the stereoiso-
mers of ketamine and metabolites on DA receptors and DA




Male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME),
ages 11–12 weeks old at the time of the experiments, were housed five
per cage in an animal room at a constant temperature (226 1°C) and a
12-hour light/dark cycle (lights on/off at 0700/1900), with food and
water provided ad libitum. Experiments were performed in the light
phase of the cycle. All experimental procedures were approved by the
University of Maryland, Baltimore, Animal Care and Use Committee,
and were conducted in full accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Drugs/Compounds
(R,S)-ketamine hydrochloride (ketamine; Sigma-Aldrich, St. Louis,
MO) was dissolved in 0.9% saline and injected i.p. with an injection
volume of 7.5 ml/kg at doses of 2, 10, or 50 mg/kg. Quinpirole
hydrochloride (Sigma-Aldrich) was dissolved in 7.5 ml/kg saline and
injected i.p. at a dose of 0.5 mg/kg. For the binding and functional
studies, (S)-ketamine, (R)-ketamine, (S)-norketamine, (R)-norketamine,
(S)-DHNK, (R)-DHNK, (2S,6S)-HNK, (2R,6R)-HNK, (2R,6S)-HNK,
and (2S,6R)-HNK were synthesized as previously described (Moaddel
et al., 2010; Zanos et al., 2016).
Tissue Distribution and Clearance Measurements of
Ketamine and Its Metabolites
C57BL/6J male mice received a single i.p. injection of ketamine
(10 mg/kg). Mice were exposed to 3% isoflurane for 30 seconds and
decapitated 10, 30, 60, 240, or 480 minutes following ketamine
injection. Trunk blood was collected in EDTA-containing tubes and
centrifuged at 8000 rpm for 6 minutes at 4°C. Plasma was collected
and stored at280°C until analysis.Whole brainswere simultaneously
collected, rinsed with phosphate-buffered saline, immediately frozen
on dry ice, and stored at 280°C until analysis.
The concentrations of ketamine and its metabolites in plasma and
brain tissue were determined by achiral liquid chromatography–tandem
mass spectrometry using a previously described protocol with slight
modifications (Paul et al., 2014;Moaddel et al., 2015). For plasma samples,
the calibration standards for (R,S)-ketamine, (R,S)-norketamine, (2R,6R;
2S,6S)-HNK, and (R,S)-DHNK ranged from 10,000 to 19.53 ng/ml. The
quantification of (R,S)-ketamine, (R,S)-norketamine, (R,S)-DHNK, and
the HNK stereoisomers was accomplished by calculating area ratios
using D4-ketamine (10 ml of 10 mg/ml solution) as the internal standard.
Whole brains were suspended in 990 ml of water:methanol (3:2, v/v),
D4-ketamine (10 ml of 10 mg/ml) was added, and the resulting mixture
was homogenized on ice with a polytronhomogenizer and centrifuged at
ABBREVIATIONS: AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANOVA, analysis of variance; DA, dopamine; DAergic,
dopaminergic; [DA]max, peak amplitude of evoked dopamine; DAT, dopamine transporter; DHNK, dehydronorketamine; FSCV, fast-scan cyclic
voltammetry; HNK, hydroxynorketamine; MK-801, (5S,10R)-(1)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine; NAc, nucleus
accumbens; NET, norepinephrine transporter; NIMH PDSP, National Institute of Mental Health Psychoactive Drug Screening Program; NMDAR, N-
methyl-D-aspartate glutamate receptor; SERT, serotonin transporter; VTA, ventral tegmental area.
160 Can et al.
21,000 g for 30minutes. The supernatantwas collected and processed
using 1-ml Oasis HLB solid-phase extraction cartridges (Waters Corp.,
Waltham, MA). The cartridges were preconditioned with 1 ml of
methanol, followed by 1 ml of water and then 1 ml ammonium acetate
(10 mM, pH 9.5). The supernatants were added to the cartridges,
followed by 1 ml of water, and the compounds were eluted with 1 ml of
methanol. The eluent was transferred to an autosampler vial for
analysis. Quality control standards were prepared at 78.125, 625, and
2,500 ng/ml.
Fast-Scan Cyclic Voltammetry
Electrodes for measuring extracellular DA concentration were
constructed by inserting a carbon fiber (7-mm diameter; Goodfellow,
Huntingdon, UK) into a glass capillary tube (1.2-mm outer diameter;
A-M Systems, Sequim, WA), pulled with a micropipette puller
(Narishige, Tokyo, Japan). Carbon fibers were then cut at approxi-
mately 100 mM past the glass tip (Heien et al., 2004). Mice were
anesthetized with urethane (1.5 g/kg, i.p.), and their heads were
positioned in a stereotaxic frame (David Kopf Instruments, Tujunga,
CA). Body temperature was continuously regulated with a rectal
thermoregulator and maintained at 37°C during surgery. Burr holes
were drilled in the skull for the implantation of three electrodes
(recording, stimulating, and reference) in the brain. The recording
electrode was placed at the level of the NAc core (11.2 anterior-
posterior, 11.1 medial-lateral, and 23.4 dorsal-ventral). A bipolar
steel stimulation electrode (Plastics1, Roanoke, VA) was positioned
ipsilaterally in the VTA (23.1 anterior-posterior,10.7 medial-lateral,
and 14.8 dorsal-ventral). An Ag/AgCl reference electrode (0.5-mm
diameter; Acros Organics, Springfield, NJ) was placed in the cortex
contralateral to the recording and stimulating electrodes. Both re-
cording and stimulating electrodes were slowly lowered into target
locations until evoked DA release was maximized. Electrode place-
ments were finalized once maximal evoked DA output was reached,
and the locations of electrodes were kept unchanged throughout the
remainder of the experiment. Recording electrodes were conditioned
by applying an inverted V wave form (20.4V to 11.3V to 20.4V,
400 V/s) at 60 Hz for 10minutes, after which the frequency of the wave
form was changed to 10 Hz and kept constant during the subsequent
procedures. In all experiments, we recorded the “background cur-
rents” produced by the inverted V wave form applied to the recording
electrode (Heien et al., 2004). This background current was subtracted
from the “faradic currents” recorded after each VTA stimulation to
derive the current attributable to DA release.
Electrical stimulation (60 Hz, 60 biphasic square pulses,
2 ms/phase, 300 mA) was applied with a constant-current isolator
(A-M Systems) to evoke DA release every 3 minutes for 30 minutes.
Baseline recordings of the extracellular concentration of DA evoked by
VTA stimulation ([DA]) were made every 3 minutes until the peak
amplitude was stabilized with less than 15% variance. Immediately
following recording of the last baseline response, each mouse received
an i.p. injection of the single drug and dose combination that it was
assigned to. Cyclic voltammograms were recorded every three
minutes for a total period of 30 minutes and analyzed with TarHeel
CV and Demon Voltammetry software (University of North Carolina,
Chapel Hill, NC and Wake Forest University, Winston-Salem, NC,).
The peak extracellular concentration of DA evoked by VTA stimula-
tion ([DA]max) obtained in the last predrug stimulation was used as
baseline, and the [DA]max following all subsequent stimulations was
calculated as a percentage change from this baseline for each individ-
ualmouse. For each stimulation, the duration of the rising phase of the
response was calculated by measuring the time that it took to reach
[DA]max starting from the initiation of electrical stimulation. The time
constant of decay (tau) was calculated by fitting the falling phase of
each response to a single exponential decay function (Yorgason et al.,
2011). These release and decay values were then normalized to the
average predrug baseline for each individual animal and reported as
percentages.
Radioligand Binding Assays
Binding profiles of (S)-, and (R)-ketamine, as well as (S)-
norketamine, (R)-norketamine, (S)-DHNK, (R)-DHNK, (2S,6S)-
HNK, (2R,6R)-HNK, (2R,6S)-HNK, and (2S,6R)-HNK for DA
receptors and monoamine transporters were performed by the
National Institute of Mental Health Psychoactive Drug Screening
Program (NIMH PDSP; University of North Carolina, Chapel Hill,
NC). For all radioligand receptor assay protocols, see the Psycho-
active Drug Screening Program web site (http://pdsp.med.unc.edu)
and previously published protocols (Besnard et al., 2012). The data
were used to calculate binding affinities expressed as Ki values.
Monoamine Transporters and Dopamine Receptor
Functional Assays
Monoamine transporter functional assays were performed by the
NIMH PDSP (for details, see http://pdsp.med.unc.edu) using a neuro-
transmitter transporter uptake assay kit (Molecular Devices, Sunnyvale,
CA). Agonist and antagonist activity at DA receptors (D1–D5) was
determined using GPCR Tango assays, also performed by the NIMH
PDSP, using previously published protocols with modifications (Kroeze
et al., 2015). In brief,HTLAcellswere transfectedwithDAreceptorTango
constructs (D1–D5) overnight and plated in Poly-L-Lys–coated 384-well
white clear-bottom cell culture plates using Dulbecco’s modified Eagle’s
medium supplemented with 1% dialyzed fetal bovine serum at a density
of 15,000 cells in 40 ml per well. Compounds (concentration responses)
were then added to cells 6 hours after plating. For antagonist activity,
reference agonist at aboutEC80 concentrationwasadded30minutes after
testing compounds. After overnight stimulation, medium and drug
solutions were removed, and BrightGlo reagents (Promega, Madison,
WI) were added to cells (20 ml/well). Luminescence was counted on a
luminescence counter after plates were incubated for 20 minutes in the
dark at room temperature.
Agonist Activity. EC50 values were determined using an agonist
dose-response formula: response 5 basal activity 1 [(Emax 2 basal
activity)/(1 1 10(LogEC50 2
agonist concentration)  Hill slope)].
Antagonist Activity. Antagonist responses were measured at a
fixed EC80 concentration of the corresponding agonist in the presence
of antagonist dilutions. IC50 values were determined using a
concentration-response formula: response5 basal activity1 [(Emax2
basal activity)/(11 10(LogIC502
agonist concentration)  Hill slope)]. IC50 was
then converted to Ki using the Cheng-Prusoff equation: Ki5 IC50/[11
(L/EC50)], where Ki is the binding affinity derived from an antagonist
concentration-response assay, IC50 is the antagonist concentration
where 50% inhibition is reached, L is the reference agonist concen-
tration used in the assay (i.e., EC50 to EC80 concentration of the
reference agonist), and EC50 is the known potency of the reference
agonist (Cheng and Prusoff, 1973).
Statistical Analysis
Data are presented as the mean 6 S.E.M. Statistical analyses were
performed by GraphPad Prism v6 (GraphPad Software, La Jolla, CA).
FSCV data were analyzed with two-way repeated-measures analysis of
variance (ANOVA).Correction formultiple comparisonswasdonebyHolm-
Sídák post-hoc test. The criterion for statistical significance was p, 0.05.
Results
Plasma and Brain Tissue Distribution and Clearance
of Ketamine and Major Metabolites. Ketamine is exten-
sively and stereoselectively transformed by multiple hepatic
cytochrome P450 isoforms into multiple metabolites (Adams
et al., 1981; Desta et al., 2012). We first sought to quantify and
compare brain and plasma concentrations of ketamine and
ketamine’s major metabolites in the C57BL/6J mouse strain
that would be used subsequently for FSCV. As shown in the
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representative chromatographic trace, quantifiable plasma concen-
trations of (R,S)-ketamine, (R,S)-norketamine, (2S,6S;2R,6R)-
HNKs, (2S,6R;2R,6S)-HNK, and (R,S)-DHNK were identified
within 10 minutes of an i.p. injection of ketamine (10 mg/kg)
(Fig. 1A). The plasma concentration-time curves are pre-
sented in Fig. 1B. The maximum plasma concentration of
(R,S)-ketamine (4.07 6 0.3 nmol/ml) was observed at the
10-minute time point, and the concentration rapidly declined,
reaching 0.036 0.03 nmol/ml at 120minutes postinjection. The
maximum plasma concentration of (R,S)-norketamine (6.906
0.5 nmol/ml) was also observed at the 10-minute time point,
indicating the rapid and extensive N-demethylation of (R,S)-
ketamine. The clearance of (R,S)-norketamine was slower
than (R,S)-ketamine, as the minimum quantifiable concen-
tration (0.07 6 0.07 nmol/ml) was measured in the plasma
sample obtained at 240 minutes postadministration. The
peak plasma concentration of (2S,6S;2R,6R)-HNK (3.16 6
0.4 nmol/ml) was observed at 30 minutes following ketamine
injection and then declined to 0.32 6 0.1 nmol/ml in the
240-minute plasma samples. The longer time to peak concen-
tration and slower clearance of (2S,6S;2R,6R)-HNK are
consistent with the primary formation of the metabolite from
ring hydroxylation of (R,S)-norketamine (Desta et al., 2012).
For (2S,6R; 2R,6S)-HNK, maximum plasma levels were
observed 30 minutes following ketamine injection (0.66 6
0.2 nmol/ml) and were rapidly cleared within 60 minutes
(0.23 6 0.2 nmol/ml). The maximum plasma concentration of
(R,S)-DHNK (0.74 6 0.08 nmol/ml) was also reached at
30 minutes postketamine administration and declined to a
concentration of 0.04 6 0.04 nmol/ml in the 120-minute
plasma sample. Plasma levels of HNK metabolites (2S,5S;
2R,5R)-HNK, (2S,4S;2R,4R)-HNK, (2S,4R;2R,4S)-HNK, and
(2S,5R;2R,5S)-HNK were below quantification limits at every
time point.
A representative chromatographic trace from the analysis of
brain tissue obtained after an i.p. injection of ketamine
(10 mg/kg) is presented in Fig. 1C. The relationships between
time following injection and measured concentrations of
Fig. 2. Changes in extracellular dopamine concen-
tration in mice that received saline, ketamine (2, 10,
or 50 mg/kg), or quinpirole (0.5 mg/kg). Black traces
of the upper row and upper color plots of the middle
row show a representative data from each treatment
group. Red traces of the upper row and the color plots
of the lower row show the last recording from the
same animal 30 minute after the drug treatment.
Time scale shown on the x-axes of the first row also
applies to the x-axes of the color plots. The y-axes of
the color plots indicates the potential applied to the
recording electrode. The pseudo-color plot scale
(z-axis) of the color plots indicates the percentage
change from the baseline DA concentration, where
DA signals are represented by the color change in
near the center (∼0.6 V) of the rising phase of the
voltage ramp. KET, ketamine; QNP, quinpirole.
Fig. 1. Plasma and brain concentrations of ketamine
and its metabolites following systemic ketamine
administration. Representative chromatograms from
the 10-minute time point from plasma (A) and brain
(C). Concentration versus time relationship for plasma
(B) and brain tissue concentrations (D) of (R,S)-
ketamine, (R,S)-norketamine, (R,S)-dehydronorketamine,
(2S,6R;2R,6R)-hydroxynorketamine, and (2S,6S;2R,6R)-
hydroxynorketamine after intraperitoneal administra-
tion of (R,S)-ketamine (10 mg/kg). The measured analyte
concentrations in the brain were normalized according
to tissue weight and are reported as umol/g of tissue.
Data are the mean 6 S.E.M. (n = 4/time point). KET,
ketamine.
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(R,S)-ketamine, (R,S)-norketamine, (2S,6S;2R,6R)-HNK, and
(2S,6R;2R,6S)-HNK are presented in Fig. 1D. The peak brain
tissue concentration of (R,S)-ketamine (7.036 0.4 nmol/g) was
observed 10 minutes following (R,S)-ketamine administration
and then declined to 0.09 6 0.05 nmol/g in the 240-minute
samples. The maximum brain tissue concentrations of (R,S)-
norketamine (3.51 6 0.17 nmol/g) and (2S,6S;2R,6R)-HNK
(1.726 0.25 nmol/g) were also observed at the 10-minute time
point and then decreased to 0.14 6 0.03 nmol/g and 0.09 6
0.02 nmol/g, respectively, at 240 minutes. Peak brain levels of
the (2S,6R;2R,6S)-HNK metabolite were observed 10 minutes
following ketamine administration (0.8 6 0.1 nmol/g) and
decreased to 0.20 6 0.04 nmol/g within 60 minutes. The
maximum brain tissue concentration of (R,S)-ketamine was
73% higher than the corresponding plasma concentration,
whereas the brain tissue concentrations of (R,S)-norketamine
and (2S,6S;2R,6R)-HNK were 49 and 45% lower than the
corresponding maximum plasma concentrations. These data
are consistent with previous observations that (R,S)-ketamine
rapidly accumulates in the brain of rats (Moaddel et al., 2015).
Although (R,S)-DHNK was also detected in brain tissues, its
levels were below quantification. This may in part be due to
circulating plasma levels of (R,S)-DHNK that are significantly
(4–8 times) lower than the other metabolites, but also due to
poor crossing of the blood-brain barrier. A potential explana-
tion for the low circulating and brain tissue concentrations of
(R,S)-DHNK was provided by a recent study reporting that
(R,S)-DHNK rapidly and irreversibly partitions into rat red
blood cells, reducing the available plasma concentrations
to less than 20% of the spiked values (Moaddel et al., 2016).
The same effect was not observed with (R,S)-ketamine, (R,S)-
norketamine, or (2S,6S;2R,6R)-HNK (Hijazi et al., 2001;
Moaddel et al., 2016). Brain levels of (2S,5S;2R,5R)-HNK,
(2S,4S;2R,4R)-HNK, (2S,4R;2R,4S)-HNK, and (2S,5R;2R,5S)-
HNK were below quantification at every time point.
Effects of Ketamine Administration on the Kinetics
of Electrically Evoked Dopamine Release. We used
FSCV to assess the magnitude and temporal dynamics of DA
release and reuptake at subsecond temporal resolution. We
electrically stimulated the VTA and recorded the resulting
changes in extracellular DA concentration in the NAc core.
Individual animals were either administered (i.p.) vehicle
(saline) or ketamine at 2, 10, or 50mg/kg, which represents the
range of subanesthetic doses that produce antidepressant
actions in rodent behavioralmodels (Browne and Lucki, 2013),
and received VTA stimulation once every 3 minutes for a
30-minute period. Changes in extracellular dopamine concen-
tration [DA] evoked by electrical stimulation in mice repre-
senting each treatment group are presented in Fig. 2.
Ketamine did not change DA release at any of the doses that
were tested. In contrast, quinpirole administration (0.5mg/kg)
induced a marked decrease in the peak amplitude of evoked
DA ([DA]max) values from the baseline (Fig. 2), as previously
reported (Stamford et al., 1991; Maina and Mathews, 2010)
and consistent with its agonist actions on D2 autoreceptors.
Group data on the effects of treatments on DA release are
presented in Fig. 3A. A two-way repeated-measures ANOVA
revealed a significant main effect of “time” (F9,2165 16.25, p,
0.0001) and an interaction of time drug treatment (F36,2165
2.52, p , 0.0001) but no significant “drug treatment” effect
(F4,24 5 1.88, p 5 0.146). Holm-Sídák post-hoc comparisons of
the effects of quinpirole administration indicated that [DA]max
values were significantly lower compared with saline, starting
at the 18th minute and lasting until the end of data collection
(Fig. 3A). No statistically significant differences between
saline- and ketamine-treated groups were observed at any
Fig. 3. Effects of ketamine on parameters of dopamine release. (A)
Percentage changes in the [DA]max of stimulation-evoked DA release at
each stimulation after the drug treatment (predrug baseline = 100). (B)
Percentage changes in rise time (the amount of time it takes to reach peak
DA concentrations) at each stimulation during the release of DA (predrug
baseline = 100). (C) Percentage changes in decay constant (tau) values at
each stimulation during the falling phase of evoked DA (predrug baseline =
100). Two-way repeated-measures ANOVA; *p, 0.05, **p, 0.01 compared
with the saline group,Holm-Sídák post-hoc test. Data are themean6S.E.M.
(saline:n = 8; KET2mg/kg : n = 4; KET 10mg/kg: n = 6; KET 50mg/kg: n = 6;
QNP: n = 5). KET, ketamine; QNP, quinpirole.
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time point (p . 0.05). Furthermore, ketamine administration
did not significantly alter [DA]max values at any time point
after injection (Fig. 3A).
A two-way repeated-measures ANOVA performed on
changes in rise-time values [time that it takes for evoked DA
concentrations to reach their maximal values ([DA]max) after
the start of each electrical stimulation] indicated no main
effect of drug treatment (F4,24 5 2.01, p . 0.05), but a
significant main effect of time (F9,216 5 3.08, p , 0.01) and
no interaction between these factors (F36,2165 0.91, P. 0.05)
(Fig. 3B). Two-way repeated-measures ANOVA on decay
constants revealed no main effect of time (F9,216 5 1.82, p .
0.05), but there was a main effect of drug treatment (F4,24 5
4.04, p , 0.05) (Fig. 3C). Although the ANOVA interaction
between these variables was not statistically significant
(F36,216 5 1.2, p . 0.05), Holm-Sídák post-hoc pairwise
comparisons between saline and all other treatment groups
were performed to assess whether decay constants were
differentially altered between treatment groups. These com-
parisons revealed that the decrease in decay constants was
significantly higher in the quinpirole treatment group com-
pared with saline group at all times from the ninth minute
onward, whereas there was no significant difference in change
in decay constants in ketamine treatment groups and the
saline group (Fig. 3C).
Overall, our results reveal that ketamine does not change
electrically evoked DA release or alter DA release and decay
kinetics in the NAc core. However, quinpirole, a D2 receptor
agonist, decreases DA release as expected from activation of
presynaptic D2 autoreceptors (Stamford et al., 1991; Maina
and Mathews, 2010).
Dopamine Receptor Binding Affinity and Functional
Activity. An in vitro affinity screening was performed to
assess affinity of (S)-ketamine, (R)-ketamine, or their metab-
olites (S)-norketamine, (R)-norketamine, (S)-DHNK, (R)-DHNK,
(2S,6S)-HNK, (2R,6R)-HNK, (2R,6S)-HNK, and (2S,6R)-HNK
on DA D1, D2, D3, D4, or D5 receptors. In the primary receptor
screening, at 10 mM concentrations, none of ketamine’s enantio-
mers or metabolites showed more than 50% inhibition of any of
the DA receptor subtypes (Table 1). Thus, no Ki determinations
were performed.
In vitro agonist and antagonist functional assays were
performed at DA D1, D2, D3, D4, and D5 receptors for (S)-
ketamine, (R)-ketamine, and their metabolites using the
GPCR Tango assays to measure agonist-mediated b-arrestin
translocation (Kroeze et al., 2015). No agonist (Fig. 4) or
antagonist (Fig. 5) actions on DA receptors were observed.
Binding Affinity and Functional Activity at Mono-
amine Transporters. In vitrobinding assayswere performed
to assess binding affinity of (S)-ketamine, (R)-ketamine, and
their metabolites to the monoamine transporters. No inhibition
of binding by ketamine enantiomers and metabolites was
observed at concentrations up to 10 mM at DAT, NET, or SERT
(Fig. 6). We also determined effects of ketamine enantiomers
and metabolites at DAT, NET, and SERT and found that they
showed no inhibitory effect on neurotransmitter transporter
activity (Fig. 7) at up to 10 mM.
Discussion
We used FSCV to study the effects of acute, subanesthetic
doses of ketamine on the magnitude and kinetics of electrical
stimulation-evoked DA release in the NAc core of anesthe-
tized mice. We also conducted a comprehensive in vitro
pharmacological screening of the binding and functional
activity of ketamine and its metabolites on DA receptors
and monoamine transporters. We observed no significant
effects of acute, systemic administration of ketamine on the
magnitude or kinetics of the electrically evoked DA concen-
trations. This contrasts with the finding by Hancock and
Stamford (1999), who observed that a 100 mM concentration
of ketamine [and in particular, (S)-ketamine] increased NAc
DA release, as measured by FSCV in rat slices. However, the
concentration of ketamine used in this previous study is
higher than brain exposure under our conditions relevant to
the antidepressant actions of ketamine. Our observed lack of
direct effects of ketamine on DA release in vivo is supported
by the pharmacological/functional activity profile of keta-
mine and its metabolites, which also showed no significant
affinity or agonist/antagonist activity on DAD1–5 receptors or
DAT, NET, or SERT.
Previous studies showed that ketamine has an affinity (Ki5
0.05–0.5 mM) for DA D2-type receptors in vitro (Kapur and
Seeman, 2002; Seeman et al., 2005), which was not identified
in our study (Table 1). We also did not find any agonist or
antagonist functional activity at theD2 receptor (Figs. 4 and 5).
Nishimura and colleagues (1998) reported that ketamine
inhibits NET (66.8 mM), DAT (62.9 mM), and SERT (162 mM)
transporters expressed in human embryonic kidney 293 cells.
In a follow-up study, they reported that (S)-ketamine shows a
greater inhibition at DAT than (R)-ketamine (Ki 5 46.9 vs.
390 mM) (Nishimura and Sato, 1999). In contrast, ketamine
exhibited no stereoselectivity for NET and SERT (Nishimura
and Sato, 1999). Consistent with these results, we did not
TABLE 1
Binding potency of ketamine’s enantiomers and metabolites at dopamine receptors
Percent values are the mean of two to five experiments, with four replicates each, and were derived from a single concentration (10 mM). Negative values are represented
as 0%.
% Inhibition
(S)-KET (R)-KET (S)-norKET (R)-norKET (S)-DHNK (R)-DHNK (2S,6S)-HNK (2R,6R)-HNK (2R,6S)-HNK (2S,6R)-HNK
Target
D1R 12 4 0 7 0 0 9 0 26 0
D2R 1 12 0 2 5 17 0 0 9 0
D3R 10 8 0 2 0 3 0 0 0 0
D4R 4 0 0 0 8 0 0 0 6 0
D5R 0 0 0 0 0 0 0 0 4 2
D1R, dopamine receptor D1; D2R, dopamine receptor D2; D3R, dopamine receptor D3; D4R, dopamine receptor D4; D5R, dopamine receptor D5; KET, ketamine; norKET,
norketamine.
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observe any binding of ketamine’s enantiomers or metabolites
to DAT, NET, or SERTwhen tested up to 10mM.Moreover, we
demonstrate no functional inhibition of ketamine’s enantio-
mers or primary metabolites on DAT, NET, or SERT (up to a
maximum concentration of 10 mΜ). Our FSCV studies con-
firmed the lack of activity of ketamine on monoamine trans-
porters and DA receptors, since we did not observe a
statistically significant effect of different doses of ketamine
on extracellular NAc DA kinetics, whereas the D2 receptor
agonist quinpirole significantly decreased the evoked release
of DA. Our pharmacological/functional screening similarly did
not provide any evidence for direct effects of ketamine and its
metabolites on DA receptor function. Taken together, our data
indicate that ketamine does not affect electrically evoked DA
release in the NAc core of anesthetized mice, and that
ketamine and its metabolites exert no significant effect on
the DAergic receptors and transporters. Additionally, no
functional effects on any of these receptors and transporters
Fig. 4. Functional agonist activity of ketamine
and ketamine metabolites at dopamine D1–5 recep-
tors compared with positive control compounds.
Functional assays of (S)-ketamine, (R)-ketamine,
(S)-norketamine, (R)-norketamine, (S)-DHNK, (R)-
DHNK, (2S,6S)-HNK, (2R,6R)-HNK, (2R,6S)-HNK,
and (2S,6R)-HNK at DA (A-B) D1, (C-D) D2, (E-F) D3,
(G-H) D4, and (I-J) D5 receptors indicated lack of
agonist action. Positive control data for each exper-
iment are indicated by colored lines. Data are the
mean 6 S.E.M. (n = 9; three independent experi-
ments and three replicates per experiment). KET,
ketamine; RLU, relative light units; SKF 81297,
(6 )-6-Chloro-2,3,4,5-tetrahydro-1-phenyl-1H-3-
benzazepine hydrobromide.
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were observed in vitro at concentrations that are relevant to
the antidepressant effects of ketamine.
Ketamine is a noncompetitive N-methyl-D-aspartate glu-
tamate receptor (NMDAR) antagonist [Ki5 0.2–1.6 mM,with
(S)-ketamine approximately 4-fold more potent than (R)-
ketamine] (Parsons et al., 1995; Ebert et al., 1997; Moaddel
et al., 2013). (S)- and (R)-norketamine are less potent
NMDAR antagonists (Ki 5 1.7–2.25 and 13–26 mM,
Fig. 5. Functional antagonist activity of ketamine and ketamine metabolites at dopamine D1–5 receptors compared with positive control compounds.
Functional assays of (S)-ketamine, (R)-ketamine, (S)-norketamine, (R)-norketamine, (S)-DHNK, (R)-DHNK, (2S,6S)-HNK, (2R,6R)-HNK, (2R,6S)-HNK
and (2S,6R)-HNK at DA (A-C) D1, (D-F) D2, (G-I) D3, (J-L) D4, and (M-O) D5 receptors indicated lack of antagonistic action. Data are the mean6 S.E.M.
(n = 9; three independent experiments and three replicates per experiment). KET, ketamine; RLU, relative light units; SCH 23390, (R)-(1)-7-Chloro-8-
hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride.
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respectively) than ketamine, whereas (2S,6S)-HNK and
(2R,6R)-HNK show limited, if any, in vitro binding or in situ
functional activity at the NMDAR (Moaddel et al., 2013;
Zanos et al., 2016). We have recently shown that the
antidepressant actions of (2R,6R)-HNK involves potentiation
of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors (Zanos et al., 2016). Our current findings
cannot preclude indirect effects of ketamine administration on
DA neurotransmission in vivo, since glutamatergic signaling
plays an important role in the regulation of the mesolimbic
DAergic system. In fact, DAergic neurons in the VTA express
both NMDAR and AMPA receptors, and these neurons receive
direct glutamatergic inputs from numerous cortical (e.g. hip-
pocampus and prefrontal cortex) and subcortical (laterodorsal
tegmental and pedunculopontine tegmental nuclei, the bed
nucleus of the stria terminalis and the superior colliculus)
brain regions (Morikawa and Paladini, 2011). Activation of
NMDARs in the VTA increases DA neuron burst firing rates
(Overton and Clark, 1992; Chergui et al., 1993), whereas
NMDAR antagonists decrease spontaneous bursts of VTA
DAergic neurons after the activation of glutamatergic inputs
to the VTA (Overton and Clark, 1992, 1997; Chergui et al.,
1994; Morikawa and Paladini, 2011). In a similar fashion, in
mutant mice lacking NMDARs specifically on DAergic neu-
rons, burst firing of VTA DAergic neurons and striatal
DA release are attenuated after electrical stimulation of
the pedunculopontine tegmental nucleus, which projects
glutamatergic inputs to the VTA (Zweifel et al., 2009).
Ketamine-induced VTA neuronal activation in vivo has
been shown to be glutamate-dependent, since administra-
tion of the AMPA receptor antagonist NBQX blocked this
effect of ketamine (Witkin et al., 2016). Moreover, indirect
modulation of the DAergic neurotransmission in other brain
regions by ketamine might also exist. The results of previ-
ous studies indicate that systemic subanesthetic doses of
ketamine increase both DA and glutamate release in the
prefrontal cortex as measured by microdialysis or DA
turnover quantification (Rao et al., 1989; Verma and
Moghaddam, 1996; Lindefors et al., 1997; Moghaddam
et al., 1997; Lorrain et al., 2003). Stereoselective effects of
(S)- and (R)-ketamine on increased electrically evoked DA
release in the caudate putamen and bed nucleus of stria
terminalis in rat brain slices have also been reported (Tso
et al., 2004). However, this occurred at a ketamine concen-
tration of 100 mM, much higher than concentrations
(,10 nmol/g) found in the brain following an antidepressant
effective dose (Fig. 1).
Other NMDAR antagonists have been shown to modulate
the midbrain DAergic system as well. In particular, systemic
administration of (5S,10R)-(1)-5-Methyl-10,11-dihydro-
5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a selective
noncompetitive NMDAR antagonist, increases extracellular
levels of DA and DA metabolism in the striatum and pre-
frontal cortex (Liljequist et al., 1991; Loscher et al., 1991;
Fig. 6. Competition binding profiles for ketamine’s enantiomers and
metabolites against the DATs (A), NETs (B), and SERTs (C). Binding
displacement by (S)-ketamine, (R)-ketamine, (S)-norketamine, (R)-norketamine,
(S)-DHNK, (R)-DHNK, (2S,6S)-HNK, (2R,6R)-HNK, (2R,6S)-HNK,
and (2S,6R)-HNK was determined at DAT using 3H-Win35428
[b-Carbomethoxy-3-b-(4-fluorophenyl)tropane)] with GBR12909 (-[2-
[Bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydro-
chloride) as a reference ligand, at NET using 3H-nisoxetine with
desipramine as a reference ligand, and at SERT using 3H-citalopram with
amitriptyline as a reference ligand. Data are the mean 6 S.E.M. (n $ 9;
three or more independent experiments and three to four replicates per
experiment). KET, ketamine.
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Bristow et al., 1993; Wolf et al., 1993). Similarly, phencycli-
dine, another noncompetitive NMDAR antagonist, increases
extracellular levels of DA or DA metabolism in the NAc,
amygdala, and prefrontal cortex (Rao et al., 1989; Bristow
et al., 1993; Hondo et al., 1994). Although these findings show
that inhibition of the NMDAR induces changes in the DA
system, they do not clarify whether these effects are due to
indirect effects of NMDAR antagonists via glutamatergic
signaling or direct effects over DA receptors and transporters.
For example, Carlsson and Carlsson (1989) showed that
MK-801-inducedhyperlocomotion is not affected bymonoamine
depletion in mice, indicating that this behavioral response
does not depend on the DAergic system. We also note that
haloperidol did not reduce ketamine-induced perceptual
changes, negative symptoms, or euphoria in healthy subjects
(Krystal et al., 1999).
In addition to NMDAR activity, ketamine has reported
effects on other receptors, including m-opioid receptors (Ki 5
26.8mM), s-opioid receptors (Ki5 26.8mM), k-opioid receptors
(Ki5 85.2 mM), d-opioid receptors (Ki5 101 mM) (Smith et al.,
1987),M1muscarinic receptors (Ki5 200mM) (Durieux, 1995),
serotonin (5-hydroxytryptamine) receptors subtype 2 (Ki 5
15 mM) (Kapur and Seeman, 2002), and nicotinic receptors
(Yamakura et al., 2000; Weber et al., 2005; Moaddel et al.,
2013). Although the binding or uptake of ketamine, or its
metabolites, to these membrane constituents might contrib-
ute to its clinical profile (Mathew et al., 2012), these Ki values
are higher than peak concentrations found in the brain or
plasma (∼8 nmol/g or 8 nmol/ml, respectively) following an
antidepressant effective dose (Fig. 1).
These results extend our knowledge of ketamine’s actions on
mesolimbic DA release and highlight the need for the study of
potential indirect interactions between glutamatergic and
DAergic neurotransmitter systems to obtain a complete picture
of ketamine’s actions relevant to both therapeutic actions and
side effects (see Grace, 2016 for a recent review).
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Fig. 7. Functional activity of ketamine and
ketamine metabolites at monoamine transporters
compared with positive control compounds.
Functional assays of (S)-ketamine, (R)-ketamine,
(S)-norketamine, (R)-norketamine, (S)-DHNK,
(R)-DHNK, (2S,6S)-HNK, (2R,6R)-HNK, (2R,6S)-
HNK, and (2S,6R)-HNK at (A-B) DAT, (C-D) NET,
and (E-F) SERT indicated lack of inhibitory
activity. Positive control data for each exper-
iment are indicated by colored lines. Data are
the mean 6 S.E.M. (n = 11; three independent
experiments and three to four replicates per
experiment). KET, ketamine.
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